Article Sidebar
Published:
Nov 3, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Inhibition of SPRY2 expression protects sevoflurane-induced nerve injury via ERK signaling pathway
Abstract
Purpose: To investigate the effect of Sprouty2 (SPRY2) on sevoflurane (SEV) induced nerve injury in rats and its potential signaling pathway.
Methods: Male Sprague-Dawley rats were divided into sham and SEV groups containing six rats per group. Neurological injury assessment and H & E staining were performed to evaluate the degree of nerve injury in the rats, while quantitative polymerase chain reaction (qPCR) and immunoblot assays were performed to confirm the expression levels of SPRY2 in hippocampus tissues. Morris water maze tests were performed to determine the degree of cognitive deficit in rats. TUNEL and immunoblot assays were performed to evaluate the effects of SPRY2 on the apoptosis of hippocampus tissues.
Results: The SPRY2 expression was elevated in sevoflurane-induced hippocampus injury (p < 0.001). Ablation of SPRY2 inhibited sevoflurane-induced hippocampal neuron apoptosis (p < 0.001). In addition, depletion of SPRY2 promoted hippocampal neuron activity and decreased apoptosis (p < 0.001). Knockdown of SPRY2 promoted ERK signaling pathway, thereby protecting against sevoflurane-induced nerve injury and cognitive deficit in the rats (p < 0.001).
Conclusion: Sevoflurane induces cognitive dysfunction and upregulates SPRY2 expression in brain tissues in rats. The SPRY2 knockdown improves SEV-induced neural injuries and cognitive deficits, inhibits hippocampal neuron apoptosis, and enhances its activity. Meanwhile, SPRY2 depletion protects SEV-induced nerve injury via the ERK pathway. Thus, Sprouty2 could serve as a promising drug target for the treatment of SEV-induced cognitive dysfunctions.
